\
&
Contact us
Starts in 4 days from now
LocationBrussels
This event aims to inform researchers from both the public and private sectors about the sixth call for proposals of the Defence-related Research Action, DEFRA, as well as a specific open call in the Human Factors domain. It will provide key insights into the objectives and themes of these calls.
During these two information days, the DEFRA team will present the objectives, themes, and modalities of the DEFRA sixth call and the Human Factors call for proposals. This is a valuable opportunity to network and gain insights relevant to funding opportunities in the defence and security sectors.
Registration is required before 20 January 2026 at 18:00, and no registrations will be accepted after this date.
Attendees without prior registration will not be allowed entry to the Royal Military Academy.
Programme
27.01.2026
28.01.2026
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.